AIMS: The prevalence of hepatic steatosis may differ between post-menopausal African-American women and non-Hispanic white women and by sex hormone binding globulin level. We examined prevalence of hepatic steatosis by race/ethnicity and associations with sex hormone binding globulin. METHODS: Participants included post-menopausal women who underwent hepatic ultrasound (n = 345) at the Michigan site of the Study of Women's Health Across the Nation, a population-based study. We examined hepatic steatosis prevalence by race/ethnicity and used logistic regression models to calculate the odds of hepatic steatosis with race/ethnicity and sex hormone binding globulin, after adjustment for age, alcohol use, waist circumference, high density lipoprotein cholesterol, triglycerides, systolic blood pressure and use of medications reported to lower intrahepatic fat. RESULTS: Fewer African-American women than non-Hispanic white women had hepatic steatosis (23 vs. 36%, P = 0.01). African-American women had lower triglyceride and low-density lipoprotein cholesterol levels, but higher blood pressure and follicle-stimulating hormone levels (P < 0.05). In the optimal-fitting multivariable models, women in the highest tertile of sex hormone binding globulin (60.2-220.3 nmol/l) had a lower odds of hepatic steatosis (odds ratio 0.43, 95% CI 0.20-0.93) compared with women in the lowest tertile of sex hormone binding globulin (10.5-40.3 nmol/l). There was an interaction between race/ethnicity and medication use whereby non-Hispanic white women using medications had three times higher odds of hepatic steatosis compared with African-American women not using medications (odds ratio 3.36, 95% CI 1.07-10.58). Interactions between race/ethnicity and other variables, including sex hormone levels, were not significant. CONCLUSIONS: Hepatic steatosis on ultrasound may be more common in post-menopausal non-Hispanic white women than African-American women and was associated with lower levels of sex hormone binding globulin.
AIMS: The prevalence of hepatic steatosis may differ between post-menopausal African-American women and non-Hispanic white women and by sex hormone binding globulin level. We examined prevalence of hepatic steatosis by race/ethnicity and associations with sex hormone binding globulin. METHODS:Participants included post-menopausal women who underwent hepatic ultrasound (n = 345) at the Michigan site of the Study of Women's Health Across the Nation, a population-based study. We examined hepatic steatosis prevalence by race/ethnicity and used logistic regression models to calculate the odds of hepatic steatosis with race/ethnicity and sex hormone binding globulin, after adjustment for age, alcohol use, waist circumference, high density lipoprotein cholesterol, triglycerides, systolic blood pressure and use of medications reported to lower intrahepatic fat. RESULTS: Fewer African-American women than non-Hispanic white women had hepatic steatosis (23 vs. 36%, P = 0.01). African-American women had lower triglyceride and low-density lipoprotein cholesterol levels, but higher blood pressure and follicle-stimulating hormone levels (P < 0.05). In the optimal-fitting multivariable models, women in the highest tertile of sex hormone binding globulin (60.2-220.3 nmol/l) had a lower odds of hepatic steatosis (odds ratio 0.43, 95% CI 0.20-0.93) compared with women in the lowest tertile of sex hormone binding globulin (10.5-40.3 nmol/l). There was an interaction between race/ethnicity and medication use whereby non-Hispanic white women using medications had three times higher odds of hepatic steatosis compared with African-American women not using medications (odds ratio 3.36, 95% CI 1.07-10.58). Interactions between race/ethnicity and other variables, including sex hormone levels, were not significant. CONCLUSIONS:Hepatic steatosis on ultrasound may be more common in post-menopausal non-Hispanic white women than African-American women and was associated with lower levels of sex hormone binding globulin.
Authors: R L Hanson; R E Pratley; C Bogardus; K M Narayan; J M Roumain; G Imperatore; A Fagot-Campagna; D J Pettitt; P H Bennett; W C Knowler Journal: Am J Epidemiol Date: 2000-01-15 Impact factor: 4.897
Authors: R C W Ma; K H Liu; P M Lam; L P Cheung; W H Tam; G T C Ko; M H M Chan; C S Ho; C W K Lam; W C W Chu; P C Y Tong; W Y So; J C N Chan; C C Chow Journal: J Clin Endocrinol Metab Date: 2010-12-29 Impact factor: 5.958
Authors: P Matafome; T Louro; L Rodrigues; J Crisóstomo; E Nunes; C Amaral; P Monteiro; A Cipriano; R Seiça Journal: Diabetes Metab Res Rev Date: 2011-01 Impact factor: 4.876
Authors: Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim Journal: J Gastroenterol Hepatol Date: 2006-01 Impact factor: 4.029
Authors: Andreas Peter; Konstantinos Kantartzis; Jürgen Machann; Fritz Schick; Harald Staiger; Fausto Machicao; Erwin Schleicher; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan Journal: Diabetes Date: 2010-09-14 Impact factor: 9.461
Authors: Lynne E Wagenknecht; Ann L Scherzinger; Elizabeth R Stamm; Anthony J G Hanley; Jill M Norris; Yii-Der I Chen; Michael Bryer-Ash; Steven M Haffner; Jerome I Rotter Journal: Obesity (Silver Spring) Date: 2009-02-19 Impact factor: 5.002
Authors: John J Dubé; Michael L Collyer; Sara Trant; Frederico G S Toledo; Bret H Goodpaster; Erin E Kershaw; James P DeLany Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Catherine Kim; Siobán D Harlow; Shengchun Kong; Carrie Karvonen-Gutierrez; Kelly Ylitalo; Bin Nan Journal: J Womens Health (Larchmt) Date: 2014-12-30 Impact factor: 2.681
Authors: Nicole E Rich; Stefany Oji; Arjmand R Mufti; Jeffrey D Browning; Neehar D Parikh; Mobolaji Odewole; Helen Mayo; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2017-09-29 Impact factor: 11.382